Cargando…

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation

Detalles Bibliográficos
Autores principales:	Salvatierra, Juan, Aomar-Millán, Ismael Francisco, Hernández-Quero, José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990485/ https://www.ncbi.nlm.nih.gov/pubmed/33782671 http://dx.doi.org/10.1016/S2665-9913(21)00064-3

Ejemplares similares

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
por: Cavalli, Giulio, et al.
Publicado: (2021)

Early experience with anti-interleukin-6 therapy in COVID-19 hyperinflammation
por: Marwah, Vikas, et al.
Publicado: (2021)

Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors
por: Gasparyan, Armen Yuri, et al.
Publicado: (2022)

Assessing the importance of interleukin-6 in COVID-19
por: Chen, Luke Y C, et al.
Publicado: (2021)

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
por: Ritchie, Andrew I, et al.
Publicado: (2020)

Assessing the importance of interleukin-6 in COVID-19 – Authors' reply
por: Leisman, Daniel E, et al.
Publicado: (2021)

Efecto del tocilizumab frente a cuidado estándar en pacientes adultos hospitalizados con neumonía por COVID-19 moderada-grave
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
por: Della-Torre, Emanuel, et al.
Publicado: (2020)

Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma
por: Sgherza, Nicola, et al.
Publicado: (2021)

Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

PIMS-TS vs. MIS-C: Diagnostic Criteria in COVID-19–Associated Hyperinflammation in Children
por: Sarkar, Mihir, et al.
Publicado: (2021)

Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab: comentario
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

An immunopathogenic perspective of interleukin-1 signaling
por: Lin, Xinwen, et al.
Publicado: (2020)

Impact of Interleukin-6 Receptor Blockade With Tocilizumab on Cardiac Injury in Patients With COVID-19: A Retrospective Cohort Study
por: Weber, Brittany N, et al.
Publicado: (2021)

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
por: Cavalli, Giulio, et al.
Publicado: (2020)

Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia
por: Quartuccio, Luca, et al.
Publicado: (2021)

Immune monitoring of interleukin-7 compassionate use in a critically ill COVID-19 patient
por: Monneret, Guillaume, et al.
Publicado: (2020)

Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019
por: Huang, Lan, et al.
Publicado: (2020)

Immunopathology of Hyperinflammation in COVID-19
por: Gustine, Joshua N., et al.
Publicado: (2021)

COVID-19, Guillain-Barré syndrome, and the vaccine. A dangerous combination()
por: Aomar-Millán, I.F., et al.
Publicado: (2021)

Management of hyperinflammation in COVID-19 patients
por: Suberviola, Borja, et al.
Publicado: (2022)

Treatment of severe covid-19 with interleukin 6 receptor inhibition
por: Rajasundaram, Skanda, et al.
Publicado: (2022)

Hyperinflammation with COVID-19: The key to patient deterioration?()()
por: Haigh, Kathryn, et al.
Publicado: (2020)

Interleukin-6 as prognosticator in patients with COVID-19
por: Grifoni, Elisa, et al.
Publicado: (2020)

Liver Injury and Elevated Levels of Interleukins, Interleukin-2 Receptor, and Interleukin-6 Predict the Severity in Patients With COVID-19
por: Luo, Kuan, et al.
Publicado: (2021)

Preemptive interleukin-6 blockade in patients with COVID-19
por: Guillén, Lucía, et al.
Publicado: (2020)

Interleukin-6 and intrapulmonary shunt
por: Perez-Vizcaino, Francisco, et al.
Publicado: (2021)

Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup
por: Rubin, Eric J., et al.
Publicado: (2021)

Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle
por: Farina, Nicola, et al.
Publicado: (2022)

Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids
por: Calò Carducci, Francesca I., et al.
Publicado: (2020)

COVID-19 Hyperinflammation: What about Neutrophils?
por: Didangelos, Athanasios
Publicado: (2020)

Frontal encephalopathy related to hyperinflammation in COVID-19
por: Cani, Ilaria, et al.
Publicado: (2020)

Delving beneath the surface of hyperinflammation in COVID-19
por: Reddy, Kiran, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eoh59b3so4gqaub4163tl5hei8